We noted a significant decline in the serum concentrations of citrulline of 32 haematopoietic stem cell transplant recipients following intensive myeloablative therapy during the first 3 weeks after transplantation when patients have oral mucositis, a markedly disturbed gut integrity (L/R ratio) and are most at risk of infection and other severe complications. Closer inspection of the citrulline concentrations of 12 patients confirmed that the decline did indeed correspond to the onset of oral mucositis and altered gut integrity. Since serum citrulline is a reliable biochemical marker of small bowel enterocyte mass in humans with villous-atrophy-associated diseases, it may prove a useful marker for intestinal mucosal damage induced by chemotherapy, allowing the relationship between gut mucosal damage and post-transplant complications including infections to be explored more readily. Mucositis is a manifestation of mucosal barrier injury and is the most frequent cause of morbidity associated with the myeloablative conditioning treatment used to prepare for haematopoietic stem cell transplantation (HSCT).
citrulline; sugar permeability test
Mucositis is a manifestation of mucosal barrier injury and is the most frequent cause of morbidity associated with the myeloablative conditioning treatment used to prepare for haematopoietic stem cell transplantation (HSCT). 1 Oral mucositis is easy to recognise, whereas detection of intestinal mucosal injury relies essentially on nonspecific symptoms such as nausea, vomiting, diarrhoea and abdominal cramps, which affect almost every HSCT recipient. An alternative means of recognising gut mucosal barrier injury is required if it is to be better understood and managed. Alterations in permeability and loss of epithelial surface are features of gut injury that can be detected by sugar permeability tests which are noninvasive and generally accepted as a surrogate marker of gut damage in patients treated for cancer. 2 However, sugar permeability tests are cumbersome and wholly dependent on patient compliance. A marker of intestinal injury that could be determined in blood would be ideal, but none has been described so far. Citrulline might prove valuable in this regard since it is an end product of glutamine metabolism of small intestinal enterocytes, cells which lack the necessary cytosolic enzymes to convert the amino acid to arginine. 3 Blood concentrations of citrulline directly reflect cell mass of the small intestine since the small intestine is the principal source of the amino acid, and it is not metabolised by the liver. 4 In mice, citrulline levels were used to quantify acute small bowel epithelial damage after single-dose whole-body irradiation. 5 The high-dose chemotherapy used to prepare patients to receive an HSCT injures the small intestine by inducing crypt apoptosis, hypoplastic villous atrophy and loss of enterocytes. 6 We determined the amino-acid profiles in the serum of a cohort of 32 HSCT recipients who had participated in a prospective randomised placebo-controlled study approved by the local Ethics Committee, the aim of which was to investigate the possible benefits of parenteral nutrition (PN) supplemented with glutamine-dipeptide. As citrulline was included, we were able to relate the concentrations temporally with oral mucositis, gut toxicity and sugar permeability tests (SPT).
Patients and methods

Patients
A total of 32 patients (12 F; 20 M) with a mean age of 48 years (range 25-65) had given their informed consent to participate in the prospective study and all had received an HLA-matched T-cell-depleted sibling HSCT to treat a haematological malignancy (AML (nine), ALL (seven), NHL (seven), MDS (three), CML (two), MPD (two), CLL (one), MF (one)). The preparative regimen consisted of idarubicin to lower the risk of relapse, 7, 8 given at a dose of 42 mg/m 2 by continuous infusion over 48 h starting 12 days before transplant (HSCT day À12), followed by 120 mg/kg cyclophosphamide (60 mg/kg per day on HSCT days À6 and À5) and 9 Gy of total body irradiation (4.5 Gy per day on HSCT days À2 and À1). Cyclosporin 3 mg/kg/day was given as prophylaxis against GVHD by continuous infusion from HSCT day À1 to þ 14, followed by 2 mg/ kg/day, until oral intake was possible. Haematopoietic growth factors were not used. Anti-infective prophylaxis consisted of ciprofloxacin and acyclovir or valaciclovir. Cotrimoxazole (sulphamethoxazole-trimethoprim) was given as Pneumocystis carinii prophylaxis. No prophylactic systemic antifungal agents were given. Cefipime or ceftazidime was administered empirically at the onset of fever. All recipients were given PN supplemented by either glutamine-dipeptide or placebo starting on HSCT day À6. Glomerular filtration rate was determined on admission by measuring renal creatinine clearance (ml/min), and was estimated thereafter from the serum creatinine using the formula of Cockroft and Gault. 9 
Mucositis assessment
Patients were monitored daily for the presence of oral mucositis evidenced by lesions, erythema, oedema, pain, bleeding, dryness and the production of viscous mucus, with each item being allocated a score of 0 or normal, to 3 or severe. The separate values were summed to yield a daily oral mucositis score (DMS) with three grades: DMS grade I (1-7 points) mild mucositis, grade II (8-14 points) moderate mucositis and grade III (414 points) severe mucositis. 10 Gut toxicity was scored likewise from 0 to 3, based on the frequency of vomiting and diarrhoea, as well as the occurrence of nausea, abdominal discomfort, faecal incontinence and volume. Summation of the separate score yielded the daily gut score (DGS): grade I (1-6 points) represents mild toxicity, grade II (7-12 points) moderate toxicity and grade III (412 points) severe toxicity. All gut toxicities following chemotherapy were ascribed to mucositis unless there was a more plausible alternative cause such as an adverse drug reaction or proven toxigenic infection.
Sugar permeability test (SPT)
An isotonic solution was prepared by dissolving 5 g lactulose (LAC), 1 g L-rhamnose (RHA), 0.2 g 3-O-methylglucose (OMG), 0.5 g D-xylose (XYL) in 100 ml demineralised water, according to good manufacturing practice, by our own hospital pharmacy. After an overnight fast, subjects emptied their bladders and then drank the solution. A light breakfast with a drink was allowed after 2 h. Urine was collected for 5 h after which the total volume passed was recorded, and aliquots of approximately 5 ml were stored at À801C until analysis was performed. The first SPT (baseline day) was performed before starting conditioning therapy, and was repeated every Wednesday after baseline on HSCT days À12, À6, 0, þ 7, þ 14 and þ 21.
Determination of the sugars in urine
The concentration of each sugar was determined using gas chromatography with flame ionisation detection with D-glucoheptose as an internal standard. 11 Data were collected on-line using Star Chromatography software (Varian, Tempe, AZ, USA) and peak areas were measured and corrected to the internal standard.
The concentration of each sugar was then estimated in mmol/l using standard calibration curves, and urinary recovery of each sugar was calculated as the percentage of intake. The coefficients of variance for LAC, XYL, RHA and OMG were 2.3, 3.7, 3.1 and 2.3%. Urinary excretion of two sugars, for example, lactulose and rhamnose, was expressed as a ratio to minimise the influence of extraneous factors such as gastric emptying and bowel transit time. The lactulose/rhamnose ratio (L/R) was used as an index of intestinal permeability or integrity with an L/R ratio of 0.02 or less being considered normal. Similarly, L-rhamnose/3-O-methylglucose (RHA/OMG) and D-xylose/3-O-methylglucose (XYL/OMG) ratios were used, respectively, as an index of absorptive capacity and mediated cellular transport, with a ratio of 0.28 12 and 0.65 13 being considered normal.
Citrulline analysis
The protocol prescribed serum to be obtained on HSCT days À12, À6, 0, þ 7, þ 14 and þ 21 for later amino-acid analysis. In practice, this was not always done. Serum taken was stored at À801C. Citrulline concentrations (mM) were measured by a standard procedure for determining amino acids using automated ion exchange column chromatography.
Data analysis
The mean and 95% confidence interval [95% CI] of DMS and DGS scores on each of the days that the SPT was performed were calculated. If these were not recorded, they were classified as missing values. Sugar ratios were first transformed to logarithms and then expressed as the mean with 95% CI. A two-sided unpaired Student's t-test was used to calculate significant differences with respect to baseline. One-way analysis of variance of citrulline concentrations (mean with 95% CI) between HSCT days was undertaken using SPSS v 11.0. ANOVA was also used to determine the role, if any, of glutamine supplementation. A P-value of o0.05 was considered statistically significant. Correlations between groups were tested by Pearson's r correlation.
Results
All patients were profoundly neutropenic (granulocytes o0.1 Â 10 9 /l) for the first 14 days after transplant. Five (16%) patients died during the first 3 weeks after transplant, two with sepsis syndrome after Streptococcus mitis bacteraemia on HSCT days þ 9 and þ 12, respectively, and one each from invasive candidiasis due to Candida albicans on HSCT day þ 13, ARDS on HSCT day þ 13 and VOD on HSCT day þ 21. Oral mucositis was present for the first 3 weeks after transplant but, unlike gut toxicity, showed a clear peak 1 week after transplant. The L/R ratio increased significantly (Po0.0001) on the day of transplant with respect to the baseline (ie 12 days after starting myeloablative therapy). The XYL/OMG and RHA/OMG ratios were also significantly decreased during the early post-transplant period (Table 1) . Some patients were unable or unwilling to drink the solution because of severe mucositis, nausea or vomiting. Citrulline concentrations were significantly (Po0.0001) decreased on the day of transplant as compared to the baseline values with the nadir being observed 1 week later.
To examine the relationship of citrulline and transplantrelated complications in more detail, we selected the 12 patients from whom blood had been obtained on each of the HSCT days À12, À6, 0, þ 7 and þ 14 for the citrulline assay. Figure 1 illustrates a clear downward trend for citrulline concentrations in all but one case (patient #12). There was no obvious difference seen between the mucositis and SPT observed in this patient and that found for the other 11 patients (data not shown). The demographics and transplant-related complications that occurred in these patients are shown in Table 2 . There is no apparent common pattern in terms of infectious complications or acute GvHD. Serum creatinine rose significantly for one patient (#4), but citrulline levels remained low. Six patients had received glutamine. The mean citrulline levels were not influenced by the use of glutamine supplementation (ANOVA, P ¼ 0.08, data not shown).
Citrulline concentrations correlated significantly with DMS r ¼ À0.36, DGS r ¼ À0.25; L/R ratio r ¼ À0.41; XYL/OMG ratio r ¼ 0.24 and RHA/OMG ratio r ¼ 0.41.
Discussion
This was a reasonably homogeneous group with respect to myeloablative regimen, prophylaxis and transplant procedure, and citrulline concentrations declined after HSCT at the same time, as oral mucositis and gut toxicity were apparent. Gut integrity, measured by L/R ratio and the absorptive capacity of rhamnose, xylose and 3-O-methylgluscose were also severely perturbed. A mean nadir of o10 mM citrulline was reached about 3 weeks after starting myeloablative therapy, that is, during the first week after transplant. This level is considered predictive of severe and extensive villous atrophy in patients with coeliac disease (Figure 1 ). 4 Furthermore, applying the thresholds that indicate the severity of villous atrophy documented in patients with coeliac disease helps illustrate the potential clinical value of declining citrulline levels after intense myeloablative therapy in HSCT recipients. 4 We could not confirm the presence of small bowel villous atrophy, for example, intestinal mucosal damage by endoscopy, as the procedure carries a high risk especially shortly after transplant. Nevertheless, when taken together, the changes in DGS (signs and symptoms), SPT (functionality) and citrulline levels (enterocyte mass) indicate that the mucosal epithelium of the small intestine is severely damaged for a prolonged period after HSC transplant, though each measure seems to reflect a different manifestation of damage to the small intestine.
Interestingly, citrulline levels on admission were lower than those found for healthy individuals (40710 mM) 4 and the L/R ratio was also higher. This might reflect residual damage to the small intestine after previous intensive chemotherapy given to induce remission of haematological malignancy or consolidate it.
Several factors are known to influence citrulline kinetics though none seem to apply to this patient population. The kidneys extract most of the citrulline released by the intestines and convert it to arginine. Citrulline levels may therefore be 'falsely' increased when creatinine clearance is below 50 ml/min. We only measured creatinine clearance once and estimated it further from serum creatinine, but only one patient showed a significant increase. Enteral feeding can induce a slight decrease in citrulline, but the patients in this study were only able to imbibe water and were being given their nutrition parenterally during the observation period. Taking blood samples for amino acids while continuing parenteral nutrition can also confound, but this is unlikely to be important for this patient population since levels continued to decline nonetheless.
These results show that low serum citrulline concentrations do coincide with and appear to correspond to severe and extensive mucosal barrier injury of the small intestine. If so, this simple test may provide another potentially useful tool for studying the relationship between mucosal barrier injury and other post-transplant complications such as malnutrition, infection and graft-versus-host disease.
